naa a22 4500 510763618 CHVBK 20180411083148.0 cr unu---uuuuu 180411e20131201xx s 000 0 eng 10.1007/s12094-013-1093-2 doi (NATIONALLICENCE)springer-10.1007/s12094-013-1093-2 SEOM guide to antiemetic prophylaxis in cancer patients treated with chemotherapy 2013 [Elektronische Daten] [J. García Gómez, M. Pérez López, M. Alonso Bermejo, Y. Escobar Álvarez, J. García Mata] Chemotherapy-induced emesis (CIE) both in the form of nausea and vomiting is one of the adverse effects most feared by patients who receive treatment, and one of the factors that most affect their quality of life and limit their functional capacity for everyday activities. Chemotherapy-induced emesis can result from many factors, depending on the treatment and the patients themselves. The best treatment for CIE is prevention, based on the use of drugs aimed at inhibiting the signal of certain neurotransmitters involved in the process. Antiemetic prophylaxis for chemotherapy of high-emetogenous potential lasting 1day includes a combination of anti-5-HT3, neurokinin-1 inhibitors and dexamethasone. Antiemetic prophylaxis for chemotherapy of moderate-emetogenous potential lasting 1day includes a combination of palonosetron and dexamethasone. Prophylaxis is not recommended for chemotherapy with minimal emetogenous potential. In the case of unforeseen or refractory emesis the use of olanzapine, metoclopramide or phenothiazine should be considered. Federación de Sociedades Españolas de Oncología (FESEO), 2013 Chemotherapy-induced emesis nationallicence Nausea and vomiting induced by chemotherapy nationallicence Serotonin antagonists nationallicence Neurokinin-1 inhibitors nationallicence Corticosteroids nationallicence Prophylaxis of emesis nationallicence García Gómez J. Medical Oncology Department, University-Hospital Complex, Orense, Spain aut Pérez López M. Medical Oncology Department, University-Hospital Complex, Orense, Spain aut Alonso Bermejo M. Medical Oncology Department, University-Hospital Complex, Orense, Spain aut Escobar Álvarez Y. Medical Oncology Department, Gregorio Marañón General University Hospital, Madrid, Spain aut García Mata J. Medical Oncology Department, University-Hospital Complex, Orense, Spain aut Clinical and Translational Oncology Springer Milan 15/12(2013-12-01), 1030-1036 1699-048X 15:12<1030 2013 15 12094 https://doi.org/10.1007/s12094-013-1093-2 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-013-1093-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- García Gómez J. Medical Oncology Department, University-Hospital Complex, Orense, Spain aut NATIONALLICENCE 700 1- Pérez López M. Medical Oncology Department, University-Hospital Complex, Orense, Spain aut NATIONALLICENCE 700 1- Alonso Bermejo M. Medical Oncology Department, University-Hospital Complex, Orense, Spain aut NATIONALLICENCE 700 1- Escobar Álvarez Y. Medical Oncology Department, Gregorio Marañón General University Hospital, Madrid, Spain aut NATIONALLICENCE 700 1- García Mata J. Medical Oncology Department, University-Hospital Complex, Orense, Spain aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/12(2013-12-01), 1030-1036 1699-048X 15:12<1030 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer